ATE391507T1 - S-methyl-dihydro-ziprasidone für die behandlung von schizophrenie - Google Patents

S-methyl-dihydro-ziprasidone für die behandlung von schizophrenie

Info

Publication number
ATE391507T1
ATE391507T1 AT06116051T AT06116051T ATE391507T1 AT E391507 T1 ATE391507 T1 AT E391507T1 AT 06116051 T AT06116051 T AT 06116051T AT 06116051 T AT06116051 T AT 06116051T AT E391507 T1 ATE391507 T1 AT E391507T1
Authority
AT
Austria
Prior art keywords
ziprasidone
schizophrenia
dihydro
methyl
treatment
Prior art date
Application number
AT06116051T
Other languages
English (en)
Inventor
Chandra A Prakash
Teresa A Smolarek
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26903852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE391507(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE391507T1 publication Critical patent/ATE391507T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AT06116051T 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidone für die behandlung von schizophrenie ATE391507T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20913600P 2000-06-02 2000-06-02
US21217200P 2000-06-16 2000-06-16

Publications (1)

Publication Number Publication Date
ATE391507T1 true ATE391507T1 (de) 2008-04-15

Family

ID=26903852

Family Applications (3)

Application Number Title Priority Date Filing Date
AT01932011T ATE343387T1 (de) 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.
AT04013380T ATE345818T1 (de) 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidone zur behandlung von psychiatrischen störungen.
AT06116051T ATE391507T1 (de) 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidone für die behandlung von schizophrenie

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT01932011T ATE343387T1 (de) 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.
AT04013380T ATE345818T1 (de) 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidone zur behandlung von psychiatrischen störungen.

Country Status (44)

Country Link
US (1) US20060287336A1 (de)
EP (3) EP1286672B1 (de)
JP (2) JP2003534381A (de)
KR (1) KR20030007824A (de)
CN (1) CN1431901A (de)
AP (2) AP1747A (de)
AR (1) AR028937A1 (de)
AT (3) ATE343387T1 (de)
AU (1) AU2001258690A1 (de)
BG (1) BG107267A (de)
BR (1) BR0111271A (de)
CA (1) CA2410618A1 (de)
CY (1) CY1105992T1 (de)
CZ (1) CZ20023860A3 (de)
DE (3) DE60133596D1 (de)
DK (1) DK1468686T3 (de)
DO (1) DOP2001000181A (de)
EA (1) EA007068B1 (de)
EC (1) ECSP024369A (de)
EE (1) EE200200670A (de)
ES (1) ES2277170T3 (de)
GE (1) GEP20053512B (de)
HN (1) HN2001000119A (de)
HR (1) HRP20020953A2 (de)
HU (1) HUP0301747A2 (de)
IL (2) IL152782A0 (de)
IS (1) IS6619A (de)
MA (1) MA26908A1 (de)
MX (1) MXPA02011862A (de)
NO (1) NO325077B1 (de)
NZ (1) NZ551012A (de)
OA (1) OA12267A (de)
PA (1) PA8518301A1 (de)
PE (1) PE20011329A1 (de)
PL (1) PL365576A1 (de)
PT (2) PT1698338E (de)
SI (1) SI1468686T1 (de)
SK (1) SK16622002A3 (de)
SV (1) SV2002000473A (de)
UA (1) UA79425C2 (de)
UY (1) UY26742A1 (de)
WO (1) WO2001091756A2 (de)
YU (1) YU90702A (de)
ZA (1) ZA200209665B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7419493B2 (en) 2002-12-13 2008-09-02 Regents Of The University Of Minnesota Scleral depressor
US7667037B2 (en) 2003-10-24 2010-02-23 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
JP2012174228A (ja) * 2011-02-24 2012-09-10 Kyocera Corp プログラム保護装置および通信装置
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9981041B2 (en) * 2016-08-23 2018-05-29 Ira Jason Salzman Ophthalmic lubricating spray

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA47467C2 (uk) * 1996-05-07 2002-07-15 Файзер Інк. Тригідрат мезилату 5-(2-(4-(1,2-бензизотіазол-3-іл)-1-піперазиніл)етил)-6-хлор-1,3-дигідро-2(1н)-індол-2-ону (зипразидону), фармацевтична композиція та спосіб лікування психічних розладів
TW491847B (en) * 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
EP0985414B1 (de) * 1998-05-26 2003-08-27 Pfizer Products Inc. Medikament zur Behandlung von Glaukoma und ischämischer Retinopathie
CA2363942A1 (en) * 1999-04-06 2000-10-12 Sepracor Inc. Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites

Also Published As

Publication number Publication date
ECSP024369A (es) 2003-02-06
EP1468686B1 (de) 2006-11-22
AP2005003272A0 (en) 2005-03-31
KR20030007824A (ko) 2003-01-23
NO20025760L (no) 2003-01-15
DE60124093D1 (de) 2006-12-07
US20060287336A1 (en) 2006-12-21
WO2001091756A2 (en) 2001-12-06
NO325077B1 (no) 2008-01-28
CY1105992T1 (el) 2011-04-06
EP1698338B1 (de) 2008-04-09
SV2002000473A (es) 2002-10-24
EP1698338A3 (de) 2006-09-20
YU90702A (sh) 2005-11-28
CA2410618A1 (en) 2001-12-06
ZA200209665B (en) 2003-11-28
WO2001091756A3 (en) 2002-09-26
BG107267A (bg) 2003-06-30
CZ20023860A3 (cs) 2004-01-14
PE20011329A1 (es) 2002-01-15
DE60133596D1 (de) 2008-05-21
DE60124791T2 (de) 2007-09-13
PL365576A1 (en) 2005-01-10
NZ551012A (en) 2008-04-30
JP2003534381A (ja) 2003-11-18
EP1468686A2 (de) 2004-10-20
GEP20053512B (en) 2005-05-10
EP1468686A3 (de) 2004-12-01
ATE343387T1 (de) 2006-11-15
OA12267A (en) 2004-01-20
SI1468686T1 (sl) 2007-04-30
IL152782A (en) 2007-10-31
EA007068B1 (ru) 2006-06-30
PA8518301A1 (es) 2002-09-17
UA79425C2 (en) 2007-06-25
JP2008056700A (ja) 2008-03-13
AU2001258690A1 (en) 2001-12-11
HRP20020953A2 (en) 2005-02-28
MXPA02011862A (es) 2003-04-10
DE60124791D1 (de) 2007-01-04
NO20025760D0 (no) 2002-11-29
EP1698338A2 (de) 2006-09-06
MA26908A1 (fr) 2004-12-20
SK16622002A3 (sk) 2004-07-07
ATE345818T1 (de) 2006-12-15
EP1286672B1 (de) 2006-10-25
HN2001000119A (es) 2001-09-11
HUP0301747A2 (hu) 2003-09-29
AP1747A (en) 2007-05-31
PT1698338E (pt) 2008-06-03
BR0111271A (pt) 2003-06-10
IS6619A (is) 2002-11-14
IL152782A0 (en) 2003-06-24
AR028937A1 (es) 2003-05-28
EE200200670A (et) 2004-08-16
EA200201168A1 (ru) 2003-06-26
CN1431901A (zh) 2003-07-23
PT1468686E (pt) 2007-01-31
UY26742A1 (es) 2001-12-28
EP1286672A2 (de) 2003-03-05
AP1831A (en) 2008-02-26
DK1468686T3 (da) 2007-03-12
ES2277170T3 (es) 2007-07-01
DOP2001000181A (es) 2002-04-15

Similar Documents

Publication Publication Date Title
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
ATE551340T1 (de) Azabicyclisch- substituierte annelierte heteroaryl-verbinungen für die behandlung von krankheiten
ATE345331T1 (de) Verbindungen verwendbar für die behandlung von entzündungskrankheiten
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE418554T1 (de) 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
DE69927823T2 (de) Hydrogel für die therapeutische behandlung von aneurysmas
ATE441417T1 (de) Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
ATE374196T1 (de) Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
ATE439844T1 (de) Kombinationen für die behandlung entzündlicher erkrankungen
DE60024649D1 (de) Verbindungen für die behandlung von ischämie
ATE286895T1 (de) Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten
DE60239558D1 (de) Kombinationen für die behandlung von immun-entzündlichen erkrankungen
DE50214540D1 (de) Stanz bei der behandlung von wunden
DE60204951D1 (de) Ccr5 antagonisten verwendbar für die behandlung von aids
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60218451D1 (de) 15-keto-prostaglandine zur behandlung arzneimittelinduzierter obstipation
DE60231107D1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
DE60105614D1 (de) Oxazinochinolone für die behandlung viraler infektionen
ATE254913T1 (de) Diacerein zur behandlung von psoriasis
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60103685D1 (de) Behandlung von Poriomania
DE60133596D1 (de) S-Methyl-Dihydro-Ziprasidone für die Behandlung von Schizophrenie
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
DE60201440D1 (de) Aryl-8-azabicyclo[3.2.1]octanes für die behandlung von depression
DE60005685D1 (de) Oxazinocarbazole zur behandlung von cns-erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties